Brain-derived neurotrophic factor exerts neuroprotective actions against amyloid β-induced apoptosis in neuroblastoma cells

Experimental and Therapeutic Medicine

Volumn 8, Issue 6, 2014, Pages 1891-1895

  Kim, Jin Hee ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Akt; Brain derived neurotrophic factor; Glycogen synthase kinase 3 ; Neuroblastoma cell; amyloid peptide

Indexed keywords

AMYLOID BETA PROTEIN [25-35]; BRAIN DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MTT ASSAY; NERVE CELL DEGENERATION; NEUROBLASTOMA; NEUROPROTECTION; NEUROTOXICITY; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION QUANTITATIVE POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

EID: 84908222445     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.2033     Document Type: Article

References (25)

1. Mesulam MM: Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24: 521-529, 1999.
2. Dickson DW: Neuropathology of Alzheimer's disease and other dementias. Clin Geriatr Med 17: 209-228, 2001.
3. Song B, Davis K, Liu XS, Lee HG, Smith M and Liu X: Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer's disease. Aging (Albany NY) 3: 846-851, 2011.
4. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 298: 789-791, 2002.
5. Yankner BA: Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16: 921-932, 1996.
6. Götz J and Ittner LM: Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9: 532-544, 2008.
7. Poo MM: Neurotrophins as synaptic modulators. Nat Rev Neurosci 2: 24-32, 2001.
8. Lindvall O, Kokaia Z, Bengzon J, Elmér E and Kokaia M: Neurotrophins and brain insults. Trends Neurosci 17: 490-496, 1994.
9. Lewin GR and Barde YA: Physiology of the neurotrophins. Annu Rev Neurosci 19: 289-317, 1996.
10. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995.
11. Sun L, Guo C, Liu D, Zhao Y, Zhang Y, Song Z, Han H, Chen D and Zhao Y: Protective effects of bone morphogenetic protein 7 against amyloid-beta induced neurotoxicity in PC12 cells. Neuroscience 184: 151-163, 2011.
12. Abràmoff MD, Magalhães PJ and Ram SJ: Image processing with ImageJ. Biophotonics International 11: 36-42, 2004.
13. Zhao R, Zhang Z, Song Y, Wang D, Qi J and Wen S: Implication of phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase-3β pathway in ginsenoside Rb1's attenuation of beta-amyloid-induced neurotoxicity and tau phosphorylation. J Ethnopharmacol 133: 1109-1116, 2011.
14. Amtul Z, Uhrig M and Beyreuther K: Additive effects of fatty acid mixtures on the levels and ratio of amyloid β40/42 peptides differ from the effects of individual fatty acids. J Neurosci Res 89: 1795-1801, 2011.
15. Hongpaisan J, Sun MK and Alkon DL: PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J Neurosci 31: 630-643, 2011.
16. Kaminsky YG, Marlatt MW, Smith MA and Kosenko EA: Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp Neurol 221: 26-37, 2010.
17. Peng S, Wuu J, Mufson EJ and Fahnestock M: Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem 93: 1412-1421, 2005.
18. Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Buchkremer G and Schott K: BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res 41: 387-394, 2007.
19. Murer MG, Boissiere F, Yan Q, Hunot S, Villares J, Faucheux B, Agid Y, Hirsch E and Raisman-Vozari R: An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. Neuroscience 88: 1015-1032, 1999.
20. Koide H, Asai T, Furuya K, Tsuzuku T, Kato H, Dewa T, Nango M, Maeda N and Oku N: Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector. Biol Pharm Bull 34: 602-608, 2011.
21. Mannoury la Cour C, Salles MJ, Pasteau V and Millan MJ: Signaling pathways leading to phosphorylation of Akt and GSK-3β by activation of cloned human and rat cerebral D2 and D3 receptors. Mol Pharmacol 79: 91-105, 2011.
22. Sánchez-Blázquez P, Rodríguez-Muñoz M and Garzón J: Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling. PLoS One 5: e11278, 2010.
23. Soriano FX, Papadia S, Hofmann F, Hardingham NR, Bading H and Hardingham GE: Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci 26: 4509-4518, 2006.
24. Grimes CA and Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426, 2001.
25. Beaulieu JM, Gainetdinov RR and Caron MG: Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49: 327-347, 2009.